DROR · Dror Ortho-Design, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance of these unaudited condensed consolidated financial statements. In order to have sufficient cash to fund the Company’s operations in the future, the Company will need to raise additional equity or debt capital and cannot provide any assurance that the Company will be successful in doing so.”View the 10-Q filed Jul 30, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2024-06-17 | Hurvitz Chaim |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock options vested fully upon the date of grant. |
Stock Option (Right to Buy)
|
21,122,239 |
| 2024-06-17 | Englander Yehuda |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock options vested two-thirds upon the date of grant, and the remainder vests on June 1, 2025, provided the Reporting Person is employed by or providing services to the Issuer or an affiliate. |
Stock Option (Right to Buy)
|
9,597,675 |
| 2024-06-17 | Shvets Moshe |
Director, Chief Technology Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock options vested two-thirds upon the date of grant, and the remainder vests on December 6, 2024, subject to earlier vesting upon the achievement of patient use objectives, provided the Reporting Person is employed by or providing services to the Issuer or an affiliate on the applicable vesting date. |
Stock Option (Right to Buy)
|
57,578,694 |
| 2024-06-17 | Haddad Eliyahu |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock options vested two-thirds upon the date of grant, and the remainder vests on December 6, 2024, subject to earlier vesting upon the achievement of patient use objectives, provided the Reporting Person is employed by or providing services to the Issuer or an affiliate on the applicable vesting date. |
Stock Option (Right to Buy)
|
95,965,715 |
| 2023-09-13 | Haddad Eliyahu |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Warrants (Direct)
Warrants will be exercisable from and after the date the Company has reserved shares of Common Stock on behalf of the holders of the warrants (the "Initial Exercise Date"). Warrants expire on the fifth anniversary of the Initial Exercise Date. |
Common Warrants
|
45,454,545 |
| 2023-09-13 | Haddad Eliyahu |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Series A Convertible Preferred Stock (Direct)
Shares of Series A Convertible Preferred Stock, par value $0.0001 per share and with a stated value of $1.10 per share (the "Preferred Stock") of Dror Ortho-Design, Inc. (formerly Novint Technologies, Inc.) (the "Company") shall be convertible, at any time and from time to time at the option of the Holder thereof, into shares of the company's common stock, par value $0.0001 per share (the "Common Stock") from and after the date the Company has reserved shares of Common Stock on behalf of the holders of the Preferred Stock. The Preferred Stock is perpetual and therefore has no expiration date. |
Series A Convertible Preferred Stock
|
454,545 |
| 2023-08-14 | Ravad Chaim |
Director |
Award↑
Filing footnotes — Common Warrants (Direct)
Pursuant to a Warrant Exchange Agreement, dated August 14, 2023, between the Company and the reporting person, simultaneously with the Share Exchange, warrants to purchase 62,071 ordinary shares of Private Dror, representing all warrants to purchase ordinary shares of Private Dror held by the reporting person, were cancelled, and the Company issued to the reporting person warrants to purchase shares of the Company's Common Stock with an exercise price of $0.033 per share (the "Warrant Exchange"). Warrants will be exercisable from and after the date the Company has reserved shares of Common Stock on behalf of the holders of the warrants (the "Initial Exercise Date"). Warrants expire on the fifth anniversary of the Initial Exercise Date. |
Common Warrants
|
228,251,826 |
| 2023-08-14 | Hurvitz Chaim |
Director |
Award↑
Filing footnotes — Common Warrants (Indirect)
Pursuant to a Warrant Exchange Agreement, dated August 14, 2023, between the Company and the reporting person, simultaneously with the Share Exchange, warrants to purchase 7,109 ordinary shares of Private Dror held by Shirat Hachaim, representing all warrants to purchase ordinary shares of Private Dror beneficially owned by the reporting person, were cancelled, and the Company issued to Shirat Hachaim warrants to purchase shares of the Company's Common Stock with an exercise price of $0.033 per share. Warrants will be exercisable from and after the date the Company has reserved shares of Common Stock on behalf of the holders of the warrants (the "Initial Exercise Date"). Warrants expire on the fifth anniversary of the Initial Exercise Date. The securities are held by Shirat Hachaim, an entity of which the reporting person is the sole owner and over whose shares the reporting person has sole voting and dispositive power . |
Common Warrants
(I)
|
42,417,309 |
| 2023-08-14 | Ravad Chaim |
Director |
Award↑
Filing footnotes — Series A Convertible Preferred Stock (Direct)
Pursuant to a Share Exchange Agreement, dated July 5, 2023 (as amended, the "Share Exchange Agreement"), by and among the Company, Dror Ortho-Design Ltd. ("Private Dror"), and the shareholders of Private Dror, the reporting person transferred 58,493 ordinary shares of Private Dror, representing all ordinary shares of Private Dror held by the reporting person, to the Company in exchange for shares of Preferred Stock (the "Share Exchange"). Shares of Series A Convertible Preferred Stock, par value $0.0001 per share and with a stated value of $1.10 per share (the "Preferred Stock") of Dror Ortho-Design, Inc. (formerly Novint Technologies, Inc.) (the "Company") shall be convertible, at any time and from time to time at the option of the Holder thereof, into shares of the company's common stock, par value $0.0001 per share (the "Common Stock") from and after the date the Company has reserved shares of Common Stock on behalf of the holders of the Preferred Stock. The Preferred Stock is perpetual and therefore has no expiration date. |
Series A Convertible Preferred Stock
|
2,150,945 |
| 2023-08-14 | Shvets Moshe |
Director, Chief Technology Officer |
Award↑
Filing footnotes — Series A Convertible Preferred Stock (Direct)
Pursuant to a Share Exchange Agreement, dated July 5, 2023 (as amended, the "Share Exchange Agreement"), by and among the Company, Dror Ortho-Design Ltd. ("Private Dror"), and the shareholders of Private Dror, the reporting person transferred 18,808 ordinary shares of Private Dror, representing all ordinary shares of Private Dror held by the reporting person, to the Company in exchange for shares of Preferred Stock (the "Share Exchange"). Shares of Series A Convertible Preferred Stock, par value $0.0001 per share and with a stated value of $1.10 per share (the "Preferred Stock") of Dror Ortho-Design, Inc. (formerly Novint Technologies, Inc.) (the "Company") shall be convertible, at any time and from time to time at the option of the Holder thereof, into shares of the company's common stock, par value $0.0001 per share (the "Common Stock") from and after the date the Company has reserved shares of Common Stock on behalf of the holders of the Preferred Stock. The Preferred Stock is perpetual and therefore has no expiration date. |
Series A Convertible Preferred Stock
|
691,620 |
| 2023-08-14 | Hurvitz Chaim |
Director |
Award↑
Filing footnotes — Series A Convertible Preferred Stock (Indirect)
Pursuant to a Share Exchange Agreement, dated July 5, 2023 (as amended, the "Share Exchange Agreement"), by and among the Company, Dror Ortho-Design Ltd. ("Private Dror"), and the shareholders of Private Dror, Shirat Hachaim Ltd ("Shirat Hachaim") transferred 16,103 ordinary shares of Private Dror, representing all ordinary shares of Private Dror beneficially owned by the reporting person, to the Company in exchange for shares of Preferred Stock (the "Share Exchange"). Shares of Series A Convertible Preferred Stock, par value $0.0001 per share and with a stated value of $1.10 per share (the "Preferred Stock") of Dror Ortho-Design, Inc. (formerly Novint Technologies, Inc.) (the "Company") shall be convertible, at any time and from time to time at the option of the Holder thereof, into shares of the company's common stock, par value $0.0001 per share (the "Common Stock") from and after the date the Company has reserved shares of Common Stock on behalf of the holders of the Preferred Stock. The Preferred Stock is perpetual and therefore has no expiration date. The securities are held by Shirat Hachaim, an entity of which the reporting person is the sole owner and over whose shares the reporting person has sole voting and dispositive power . |
Series A Convertible Preferred Stock
(I)
|
592,150 |
| 2023-08-14 | Shvets Moshe |
Director, Chief Technology Officer |
Award↑
Filing footnotes — Common Warrants (Direct)
Pursuant to a Warrant Exchange Agreement, dated August 14, 2023, between the Company and the reporting person, simultaneously with the Share Exchange, warrants to purchase 7,109 ordinary shares of Private Dror, representing all warrants to purchase ordinary shares of Private Dror held by the reporting person, were cancelled, and the Company issued to the reporting person warrants to purchase shares of the Company's Common Stock with an exercise price of $0.033 per share (the "Warrant Exchange"). Warrants will be exercisable from and after the date the Company has reserved shares of Common Stock on behalf of the holders of the warrants (the "Initial Exercise Date"). Warrants expire on the fifth anniversary of the Initial Exercise Date. |
Common Warrants
|
26,141,712 |